Chongqing University Cancer Hospital Chongqing, Chongqing
Y. Song1,2, Y. Wang1, J. Sui3, B. Long1, X. Shu1, X. Zhang1, F. Wang1, C. Wang1, M. Hu1, M. Q. Yang4, and Y. Wang1; 1Radiation Oncology Center,Chongqing University Cancer Hospital, Chongqing, China, 2College of Medicine, Chongqing University, Chongqing, China, 3Department of Radiation Oncology, Chongqing Cancer Hospital & Cancer Institute, Chongqing, China, 4Radiation Physics Center, Chongqing University Cancer Hospital, Chongqing, China
Purpose/Objective(s): We aimed to evaluate the efficacy and toxicities after NBI combined with MRI-guided individualized clinical target volume (CTV) delineataion in eccentric nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy (IMRT). Materials/
Methods: This is a prospective, single-center clinical trial that plans to include 60 patients with a nasopharyngeal mass confIned to one side of the nasopharynx or did not exceed the midline. Patients with negative contralateral retropharyngeal lymph nodes and no clivus involvement were eligible. The patients were enrolled if both NBI endoscopy and MRI showed eccentric NPC. Patients with contralateral tissue mucosal abnormalities detected by NBI and confirmed by biopsy were excluded. Then the patients were randomly divided into an experimental group (individualized CTV) or a control group (conventional CTV) to evaluate the efficacy and safety of the two groups.For individualized CTV, the contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx (not include entire nasopharynx mucosa); The CTV2 was defined as potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess. The primary endpoint are acute adverse reactions and control rate of non-irradiated area. The secondary objectives are 3-year local recurrence-free survival(LRFS),3-year overall survival (OS),3-year progress-free survival(PFS), quality of life. As of January 2024,61% of the planned 60 subjects have been enrolled. ClinicalTrials.gov Identifier: NCT06167109. Results: Clinical trial in progress. Conclusion: Clinical trial in progress.
